Waldenstrom's Macroglobulinemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Conditions: Asymptomatic COVID-19 Infection Laboratory-Confirmed; B-Cell Neoplasm; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Symptomatic COVID-19 Infection Lab oratory-Confirmed; Waldenstrom Macroglobulinemia Interventions: Drug: Ibrutinib; Other: Quality-of-Life Assessment Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2020 Category: Research Source Type: clinical trials
